1. Home
  2. CVLT vs ACAD Comparison

CVLT vs ACAD Comparison

Compare CVLT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Commvault Systems Inc.

CVLT

Commvault Systems Inc.

HOLD

Current Price

$103.78

Market Cap

4.1B

Sector

Technology

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.22

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CVLT
ACAD
Founded
1996
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
3.8B
IPO Year
2006
2000

Fundamental Metrics

Financial Performance
Metric
CVLT
ACAD
Price
$103.78
$22.22
Analyst Decision
Buy
Buy
Analyst Count
18
22
Target Price
$139.53
$30.55
AVG Volume (30 Days)
811.4K
1.6M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
1.58
0.02
Revenue
$1,183,690,000.00
$726,437,000.00
Revenue This Year
$13.29
$18.80
Revenue Next Year
$13.20
$11.70
P/E Ratio
$84.85
$1,116.75
Revenue Growth
18.89
40.45
52 Week Low
$71.75
$19.69
52 Week High
$200.68
$28.35

Technical Indicators

Market Signals
Indicator
CVLT
ACAD
Relative Strength Index (RSI) 63.25 51.96
Support Level $80.85 $21.04
Resistance Level $129.23 $22.91
Average True Range (ATR) 4.03 0.73
MACD 0.55 0.03
Stochastic Oscillator 86.17 57.89

Price Performance

Historical Comparison
CVLT
ACAD

About CVLT Commvault Systems Inc.

CommVault Systems Inc provides data and information management software applications and services. The firm sells software licenses and services to large global enterprises, small- and midsize businesses, and government agencies through both its salesforce and its network of reseller partners. Its software solutions include Cleanroom Recovery, HyperScale X, Air Gap Protect, Compliance, Cloud Rewind, and Clumio Backtrack. The company operates in the United States and exports to many other countries.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: